Rho AI Software for Osteoporosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial evaluates how well a new artificial intelligence software, called Rho AI, can detect osteoporosis (a condition where bones become weak and brittle) in medical images. Researchers will analyze 800 anonymous images from individuals who underwent surgeries such as joint replacement or spine fusion to determine the software's accuracy in identifying osteoporosis. Images from those who have had these surgeries might be included in the study. The goal is to enhance early detection of osteoporosis, aiding in better management of the condition. As an unphased trial, this study provides a unique opportunity to contribute to the development of innovative technology that could transform osteoporosis detection.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this software is safe for identifying osteoporosis?
Research has shown that Rho AI Software is generally safe because it doesn't involve administering any treatment or medication. Instead, it uses artificial intelligence to analyze existing medical images to help identify signs of osteoporosis. Participants, therefore, need not worry about physical side effects.
Radiologists in Canada have used Rho AI Software in real-world settings, demonstrating its compatibility with medical practices. Since the software only analyzes images, it poses no risk to a patient's health. Its function is to assist doctors in spotting signs of low bone density, which could lead to osteoporosis.
Overall, Rho AI Software is non-invasive and enhances detection rates without any known safety concerns.12345Why are researchers excited about this trial?
Unlike traditional osteoporosis treatments that often involve medications like bisphosphonates or hormone therapy, Rho AI Software is a cutting-edge approach that utilizes artificial intelligence to detect osteoporosis. This software offers the potential for earlier and more accurate diagnosis by analyzing bone density patterns and other risk factors with advanced algorithms. Researchers are excited about this method because it could lead to more personalized treatment plans and ultimately better patient outcomes by catching the disease before significant bone loss occurs.
What evidence suggests that this software is effective for identifying osteoporosis?
Studies have shown that Rho AI software, which participants in this trial will use, can help detect osteoporosis by analyzing x-ray images. This tool uses existing x-ray data to identify individuals at risk for low bone strength, crucial for diagnosing osteoporosis. Research indicates that Rho could enhance early detection by identifying potential cases before they become serious. In a survey, 78% of healthcare professionals found Rho helpful for patient care, and 74% would use its screening information. These findings suggest that Rho AI software could effectively spot osteoporosis early.12567
Who Is on the Research Team?
James Bernatz, MD
Principal Investigator
UW School of Medicine and Public Health
Are You a Good Fit for This Trial?
This trial is for individuals with de-identified images from January 2007 to January 2024 that can be used to test the Rho AI software's ability to detect osteoporosis. Specific eligibility criteria are not provided.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
De-identified x-ray images are collected and processed through the Rho AI software to identify osteoporosis or osteopenia
Follow-up
Participants are monitored for safety and effectiveness after data collection
What Are the Treatments Tested in This Trial?
Interventions
- Rho AI Software
Trial Overview
The study aims to validate the effectiveness of Rho AI software in identifying cases of osteoporosis using a set of 800 de-identified images collected over a period spanning from January 2007 to January 2024.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Citations
AI Screening Tool Based on X-Rays Improves Early ...
By leveraging existing x-ray data to identify at-risk patients, Rho holds significant potential to enhance the early detection of osteoporosis.
Opportunistic Screening of Low Bone Mineral Density From ...
By initiating a fracture risk assessment, Rho could help improve low osteoporosis screening rates. Here, we describe the development of Rho, report on its ...
16 BIT - RHO
Rho utilizes routinely captured x-rays to opportunistically identify patients at risk of low bone mineral density.
AI Screening Tool Based on X-Rays Improves Early ...
... Rho has the potential to improve low screening rates for osteoporosis by leveraging existing x-ray data.
AI Tool Aids Opportunistic Screening of Low Bone Density ...
Of the survey's 51 respondents, 78% believed Rho was beneficial for patient care and 74% said they would use Rho screening information. “ ...
AI Technology Developed by CAR Members Deployed in ...
A new AI-based tool for screening patients for bone mineral density is being evaluated at Canada's largest research hospital.
7.
hospitalnews.com
hospitalnews.com/radiologists-in-canada-are-using-an-ai-driven-screening-tool-to-improve-population-bone-health/Radiologists in Canada are using an AI-driven screening ...
Using a new, artificial intelligence-driven screening tool, Rho TM , radiologists now have the means and opportunity to help boost these screening rates.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.